<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3377">
  <stage>Registered</stage>
  <submitdate>27/11/2011</submitdate>
  <approvaldate>27/11/2011</approvaldate>
  <nctid>NCT01482507</nctid>
  <trial_identification>
    <studytitle>Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis</studytitle>
    <scientifictitle>Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IMM 10-0120 (DWI101)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Subject has Rheumatoid Arthritis as defined by the ACR/Eular criteria

          -  Subject is able to understand and comply with study protocol

          -  Active disease as defined by DAS28&gt; 3.0

          -  Disease duration less than 12 months

          -  If female, subject is either not of childbearing potential, or is of childbearing
             potential and is practicing an approved method of birth control throughout the study

          -  subject is judged to be in good health as determined by the PI based upon results of
             medical history, laboratory profile and physical examination.

          -  Prednisone dose 10mg or less, dose stable for 28 days prior to baseline</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inflammatory arthropathy other than Rheumatoid Arthritis

          -  Inactive disease as evidenced by DAS 28 CRP and / or ESR &lt; 2.5

          -  Prednisone dose greater than 10mg within 28 days prior to baseline

          -  Intra-articular steroid within 28 days prior to baseline visit

          -  IV Methyl-prednisone within 28 days prior to baseline visit

          -  Any contra-indication to Magnetic Resonance Imaging

          -  Permanent Pacemaker

          -  Intracerebral aneurysm clip

          -  Claustrophobia to the extent that patient cannot manage MRI investigations

          -  Implanted metallic device

          -  Cochlear implant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2012</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Optimus Clinical Research - Kogarah</hospital>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Optimus Clinical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Arthritis Australia, Abbott Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diffusion Weighted Imaging (DWI) MRI will assist in differentiating poor prognosis bone
      oedema more effectively than traditional T2 weighted MRI in patients with early Rheumatoid
      Arthritis (RA).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01482507</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Bird, Dr</name>
      <address>Optimus Clinical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>